Education
About Us
Working with TipRanks
Follow Us
Orasure Technologies (OSUR)
NASDAQ:OSUR
Top Page
Orasure Technologies
(NASDAQ:OSUR)
52Neutral
Orasure Technologies (OSUR) vs. S&P 500 (SPY)
Market Cap
$252.82M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)25.3
Beta (1Y)0.81
Revenue Growth-54.17%
EPS Growth-135.78%
CountryUS
Employees638
SectorHealthcare
Sector Strength78
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.26
Shares Outstanding74,800,130
10 Day Avg. Volume1,440,671
30 Day Avg. Volume1,029,561
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.35
Price to Cash Flow (P/CF)576.40
P/FCF Ratio469.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.00Price Target Upside47.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Orasure Technologies Business Overview & Revenue Model
Company DescriptionOraSure Technologies, Inc. is a leading innovator in the development, manufacture, and distribution of point-of-care diagnostic tests and specimen collection devices. Serving sectors such as healthcare, diagnostics, and public health, Orasure's core products include rapid diagnostics for infectious diseases, oral fluid collection devices, and laboratory services. The company is recognized for its pioneering work in developing the first FDA-approved rapid HIV test and continues to expand its product offerings in infectious disease testing and molecular solutions.
How the Company Makes MoneyOraSure Technologies generates revenue through the sale of its diagnostic products and specimen collection devices. The company's primary revenue streams include sales of rapid diagnostic tests for infectious diseases, such as HIV and hepatitis C, and its oral fluid collection systems used in various testing applications. Orasure also earns income from its laboratory services, which provide diagnostic testing and analysis. Significant partnerships with governmental and non-governmental organizations, healthcare providers, and research institutions contribute to its earnings by facilitating the distribution and adoption of its diagnostic solutions. Additionally, the company benefits from strategic collaborations and licensing agreements that enhance its market reach and product development capabilities.
Orasure Technologies Financial Statement Overview
Summary
Orasure Technologies faces operational challenges with declining revenue and negative profitability, but maintains a strong balance sheet with low leverage and high equity, providing some financial stability. Cash flow issues indicate struggles in operational efficiency.Income Statement
Orasure Technologies has experienced a significant decline in total revenue from $405.47 million in 2023 to $185.83 million in 2024, a decrease of 54.15%. The gross profit margin has improved significantly, likely due to reduced revenue reporting errors ($78.36 million gross profit on $185.83 million revenue), but the company is operating at a loss with a negative EBIT and net income. This indicates challenges in profitability and operational efficiency.45
Neutral
Balance Sheet
The company's balance sheet is relatively strong with a high equity ratio of 85.57% and low debt levels, as evidenced by a debt-to-equity ratio of 0.04. Stockholders' equity is solid, but the decrease in total assets over the year suggests potential concerns about asset utilization. Nevertheless, the company's low leverage and strong equity position are positive indicators of financial stability.70
Positive
Cash Flow
The operating cash flow has drastically decreased from $141.58 million in 2023 to $27.37 million in 2024, indicating challenges in generating cash from operations. However, the company has maintained positive free cash flow, albeit significantly lower than the previous year. The free cash flow to net income ratio indicates cash inefficiency, as the net income is negative.55
Neutral
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 184.61M | 185.83K | 405.47M | 387.48M | 233.67M | 171.72M | Gross Profit |
| 102.59M | 78.36M | 179.42M | 147.64M | 117.60M | 101.87M | EBIT |
| -1.64M | -28.25K | 32.68M | -4.67M | -11.65M | -6.28M | EBITDA |
| 15.26M | -28.25K | 64.35M | 10.29M | 9.00K | 3.44M | Net Income Common Stockholders |
| 11.37M | -19.50K | 53.66M | -17.93M | -23.00M | -14.92M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 156.57M | 267.76M | 290.41M | 110.85M | 153.04M | 209.40M | Total Assets |
| 315.57M | 479.66M | 482.85M | 444.71M | 460.99M | 454.47M | Total Debt |
| 0.00 | 14.60M | 13.50M | 12.55M | 12.27M | 6.13M | Net Debt |
| -88.44M | -253.16M | -276.90M | -71.43M | -104.49M | -154.67M | Total Liabilities |
| 32.19M | 69.32M | 52.17M | 81.08M | 80.46M | 55.90M | Stockholders Equity |
| 283.38M | 410.34M | 430.67M | 363.62M | 380.53M | 398.57M |
| Cash Flow | Free Cash Flow | ||||
| 64.00M | 23.58K | 131.28M | -111.11M | -83.50M | -23.12M | Operating Cash Flow |
| 68.63M | 27.37K | 141.58M | -47.20M | -35.38M | 5.81M | Investing Cash Flow |
| -2.98M | -39.03K | 66.15M | 21.09M | -5.50M | -14.03M | Financing Cash Flow |
| -4.42M | -4.18K | -3.02M | -3.83M | -2.82M | 92.48M |
Orasure Technologies Technical Analysis
Negative
3.38
Price Trends
3.73
Negative
3.85
Negative
4.09
Negative
Market Momentum
-0.12
Positive
46.45
Neutral
57.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Negative. The current price of 3.38 is below the 20-day moving average (MA) of 3.60, below the 50-day MA of 3.73, and below the 200-day MA of 4.09, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 46.45 is Neutral, neither overbought nor oversold. The STOCH value of 57.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 63 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $238.23B | 17.96 | 30.95% | 1.69% | 4.59% | 134.50% | |
73 Outperform | $65.31B | 38.13 | 6.92% | 1.71% | 5.89% | 42.05% | |
70 Outperform | $198.74B | 32.15 | 13.15% | 0.30% | 0.05% | 6.87% | |
67 Neutral | $14.04B | 19.80 | 15.78% | ― | 1.75% | 50.25% | |
52 Neutral | $252.82M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
46 Neutral | $2.52B | ― | -50.74% | ― | -7.03% | -20233.78% |
* Healthcare Sector Average
Performance Comparison
OSUR
Orasure Technologies
3.38
-3.65
-51.92%
ABT
Abbott Laboratories
130.28
12.52
10.63%
BDX
Becton Dickinson
223.82
-10.88
-4.64%
HOLX
Hologic
61.10
-15.23
-19.95%
QDEL
QuidelOrtho
37.29
-9.97
-21.10%
TMO
Thermo Fisher
512.65
-79.06
-13.36%
Orasure Technologies Earnings Call Summary
Earnings Call Date: Feb 25, 2025 | % Change Since: -15.50% | Next Earnings Date: May 7, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth and strategic acquisitions, which are positive indicators. However, external uncertainties such as funding issues and challenges in specific segments present potential risks. The sentiment is balanced between optimistic growth prospects and cautiousness due to external factors.Highlights
Revenue Growth
OraSure Technologies reported Q4 revenue of $37.4 million, with core revenue growing 10% year-over-year. Diagnostics revenue increased by 9% and sample management solutions revenue grew by 14%.
Acquisition of Sherlock Biosciences
OraSure acquired Sherlock Biosciences to expand its innovation pipeline with a molecular diagnostic platform. The first molecular self-test for chlamydia and gonorrhea is expected to be submitted to the FDA by end of 2025.
FDA Approval for Expanded HIV Testing
OraSure secured FDA approval to expand the age range for its OraQuick HIV self-test, increasing accessibility to individuals aged 14 and older.
Positive Cash Flow from Operations
The company generated positive cash flow from operations in its core business during Q4, demonstrating progress in operating efficiency and cost savings initiatives.
Strong International Performance
OraSure's international diagnostic business delivered strong performance, with 2024 being a record year for revenue, surpassing the previous high set in 2023.
Lowlights
Uncertainty in HIV Testing Programs
Uncertainty in HIV testing programs due to US funding freezes for foreign aid has caused disruptions, particularly affecting programs supported by PEPFAR.
Impact of NIH Funding Reductions
Potential reductions to NIH research funding create uncertainty for academic and research organizations using OraSure's sample management solutions.
Gross Margin Challenges
Non-GAAP gross margin was slightly below expectations due to lower-than-expected margins in the risk assessment business and higher-than-expected scrap expense.
Winding Down of Risk Assessment Business
OraSure is exiting its risk assessment testing business, which resulted in a $1 million inventory reserve expense.
Company Guidance
During the Q4 2024 earnings call, OraSure Technologies provided guidance and updates on their strategic initiatives and financial performance. The company reported total revenue of $37.4 million, with core revenue increasing by 10% year-over-year to $36.5 million. Specifically, diagnostic product sales grew by 9%, generating $18.8 million, while sample management solutions revenue rose by 14% to $14.8 million. The company highlighted notable achievements, including the acquisition of Sherlock Biosciences and FDA approval for expanded use of the OraQuick HIV self-test. Despite facing uncertainties in global markets, OraSure is focused on strategic transformation, aiming for significant gross margin expansion towards 50% in 2025 through operational efficiencies and innovations. For Q1 2025, the company projects total revenue between $27.5 million and $31.5 million. They also emphasized the impact of external factors such as potential reductions in NIH funding and changes to US foreign aid programs, particularly PEPFAR, which could affect their international diagnostics revenue.Orasure Technologies Corporate Events
M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
OraSure Technologies Reports Q4 2024 Financial Results
Neutral
Feb 25, 2025
On February 25, 2025, OraSure Technologies announced its financial results for the fourth quarter of 2024, reporting a 10% growth in core revenue despite a 51% decline in total net revenues compared to the previous year. The company highlighted its strategic transformation and acquisition of Sherlock Biosciences as key drivers for future growth, aiming to expand its product portfolio and customer base while addressing uncertainties related to government funding.
M&A TransactionsBusiness Operations and Strategy
OraSure Technologies Acquires Sherlock Biosciences for Growth
Positive
Dec 19, 2024
OraSure Technologies announced the acquisition of Sherlock Biosciences, a move that is expected to enhance their portfolio with next-generation molecular diagnostics. This strategic acquisition aligns with OraSure’s mission to improve access and affordability in healthcare through innovative, instrument-free molecular self-tests, potentially increasing their revenue starting in 2026, subject to regulatory approvals.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.